ISPOR - CV4 BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION

Full Text

CV4 BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION

Abstract

Authors

P Lapuerta A Gomez S Franklin

Back to Volume 10, Issue 6

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now